期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 7, 期 11, 页码 1627-1645出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.7.11.1627
关键词
beta-cells; clinical trials; insulin independence; islet transplantation; Type 1 diabetes
资金
- NCRR NIH HHS [M01RR16587, U42 RR016603] Funding Source: Medline
- NIDDK NIH HHS [1R01DK25802-21, R01DK025802, 5R01DK55347, 5R01DK056953] Funding Source: Medline
- PHS HHS [1R01D59993-04] Funding Source: Medline
Significant progress has been made in the field of P-cell replacement therapies by islet transplantation in patients with unstable Type 1 diabetes mellitus (T1DM). Recent clinical trials have shown that islet transplantation can reproducibly lead to insulin independence when adequate islet numbers are implanted. Benefits include improvement of glycemic control, prevention of severe hypoglycemia and amelioration of quality of life. Numerous challenges still limit this therapeutic option from becoming the treatment of choice for T1DM. The limitations are primarily associated with the low islet yield of human pancreas isolations and the need for chronic immunosuppressive therapies. Herein the authors present an overview of the historical progress of islet transplantation and outline the recent advances of the field. Cellular therapies offer the potential for a cure for patients with T1DM. The progress in P-cell replacement treatment by islet transplantation as well as those of emerging immune interventions for the restoration of self tolerance justify great optimism for years to come.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据